Title
Category
Credits
Event date
Cost
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
  • CMHC
  • TME
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. MASH represents a metabolic-driven array of multi-organ pathology that intersects with obesity, prediabetes, type 2 diabetes, and cardiovascular ailments. Many agents are currently in development for treatment of MASH, including glucagon-like peptide-1 receptor agonists (GLP1-Ras).
Clinical Insights into Psoriasis in Patients of Color: Bringing New Data to Light
  • LivDerm
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Various gaps in the management of psoriasis in patients with SOC persist due to a lack of training for dermatology practitioners. As a result, patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden. Given the predicted increase in the SOC population over the next decades, improving the diagnosis and management of psoriasis in these patients is critical.

Pages